The first person has been treated with a much-anticipated new gene therapy that aims to turn back the clock on aging cells. The trial is aimed at retinal cells, with the hope that encouraging them to behave like they are young again could improve vision in affected patients. If it proves safe, it could open the door to a whole range of treatments based on the emerging field of cellular rejuvenation. To understand more about this cutting-edge research, Madeleine Finley spoke with Science editor Ian Sample and John Knoepfler, professor of cell biology and human anatomy at the University of California, Davis.
